{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:36Z","timestamp":1793068476288,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1053\/j.semnuclmed.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,11,24]],"date-time":"2019-11-24T23:10:18Z","timestamp":1574637018000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Targeted Alpha-Particle Therapy for Hematologic Malignancies"],"prefix":"10.1053","volume":"50","author":[{"given":"Joseph G.","family":"Jurcic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0001","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00062752-200107000-00001","article-title":"Hematologic malignancies","volume":"8","author":"Gilliland","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0002","series-title":"SEER Cancer Statistics Review, 1975-2016","author":"Howlader","year":"2019"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0004","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0005","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariate cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0006","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0007","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0008","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0009","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI111756","article-title":"Heterogeneity of clonogenic cells in acute myeloblastic leukemia","volume":"75","author":"Sabbath","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0010","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.141.8.2797","article-title":"Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells","volume":"141","author":"Simmons","year":"1988","journal-title":"J Immunol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0011","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1084\/jem.152.4.842","article-title":"Human homolog of murine T200 glycoprotein","volume":"152","author":"Omary","year":"1980","journal-title":"J Exp Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","article-title":"CD45: A critical regulator of signaling thresholds in immune cells","volume":"21","author":"Hermiston","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymph"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy, in Stohl W (ed): B cell trophic factors and B cell antagonism in autoimmune disease","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun. Basel, Karger"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0016","first-page":"177","article-title":"CD138 (syndecan-1) expression in health and disease","volume":"29","author":"Palaiologou","year":"2014","journal-title":"Histol Histopathol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s002590050306","article-title":"Radioimmunotherapy with alpha-emitting nuclides","volume":"25","author":"McDevitt","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0018","first-page":"1722","article-title":"Preparation of \u03b1-emitting 213Bi-labeled antibody constructs for clinical use","volume":"40","author":"McDevitt","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0969-8043(02)00167-7","article-title":"Design and synthesis of 225Ac radioimmunopharmaceuticals","volume":"57","author":"McDevitt","year":"2002","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.2967\/jnumed.114.138347","article-title":"Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for \u03b1-particle radioimmunotherapy of cancer","volume":"55","author":"Maguire","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0021","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0022","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/0008-5472.CAN-04-3096","article-title":"Efforts to control the errant products of a targeted in vivo generator","volume":"65","author":"Jaggi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0023","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ijrobp.2005.11.036","article-title":"Mitigation of radiation nephropathy after internal \u03b1-particle irradiation of kidneys","volume":"64","author":"Jaggi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0024","first-page":"1","article-title":"Production of [211At]-astatinated radiopharmaceuticals and applications in targeted \u03b1-particle therapy","volume":"28","author":"Gu\u00e9rard","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0025","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2007-01-066803","article-title":"Targeted cancer therapy with a novel low-dose rate \u03b1-emitting radioimmunoconjugate","volume":"110","author":"Dahle","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0026","first-page":"6761","article-title":"Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies","volume":"52","author":"Caron","year":"1992","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0027","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V83.7.1760.1760","article-title":"A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity","volume":"83","author":"Caron","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0028","first-page":"372","article-title":"Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia","volume":"6","author":"Jurcic","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0029","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk Lymph"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","article-title":"Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias","volume":"32","author":"Burke","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0031","first-page":"166","article-title":"Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry","volume":"40","author":"Nikula","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0032","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0033","first-page":"1935","article-title":"Pharmacokinetics and dosimetry of an \u03b1-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia","volume":"40","author":"Sgouros","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0034","first-page":"27","article-title":"Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia","volume":"42","author":"Kolbert","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0035","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0036","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood.V118.21.768.768","article-title":"Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)","volume":"118","author":"Jurcic","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0037","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood.V128.22.4050.4050","article-title":"Phase I trial of targeted alpha-particle therapy with actinium-225 (225Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML)","volume":"128","author":"Jurcic","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0038","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0039","series-title":"Proceedings of the 10th International Symposium of Targeted Alpha Therapy; 2017 May 30-June 1","first-page":"22","article-title":"Efficacy of Ac-225-labeled anti-CD33 antibody in acute myeloid leukemia (AML) correlates with peripheral blast count","author":"Berger","year":"2017"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0040","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jmir.2019.03.113","article-title":"A phase 2 study of actinium-225 (225Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML)","volume":"50","author":"Atallah","year":"2019","journal-title":"J Med Imaging Radiat Sci"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0042","series-title":"Proceedings of the 110th Annual Meeting of the American Association for Cancer Research 2019 March 29-April 3","first-page":"3808","article-title":"225Ac-CD33 radioimmunotherapy potently increases the sensitivity of resistant acute myeloid leukemia lines to the Bcl-2 inhibitor venetoclax by mediating a reduction in cellular Mcl-1 levels","author":"Garg","year":"2019"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0043","doi-asserted-by":"crossref","first-page":"218","DOI":"10.18632\/oncotarget.817","article-title":"Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells","volume":"4","author":"Roscher","year":"2013","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0044","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","article-title":"Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model","volume":"125","author":"Green","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2005-11-4757","article-title":"Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7\/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25","volume":"108","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0046","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-009-1197-7","article-title":"Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab","volume":"37","author":"Dahle","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0047","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijrobp.2008.05.029","article-title":"Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuxetan-ibritumomab versus external beam X-radiation","volume":"72","author":"Dahle","year":"2008","journal-title":"In J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0048","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1535-7163.MCT-16-0251","article-title":"In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia","volume":"15","author":"Hagemann","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0049","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.18632\/oncotarget.2986","article-title":"\u03b1-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma","volume":"6","author":"Teiluf","year":"2015","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019001250","article-title":"The alpha emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model","author":"O'Steen","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0051","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","article-title":"213Bi radioimmunotherapy with an anti-CD138 monoclonal antibody in a murine model of multiple myeloma","volume":"54","author":"Ch\u00e9rel","year":"2013","journal-title":"J Nucl Med"},{"issue":"Suppl","key":"10.1053\/j.semnuclmed.2019.09.002_bib0052","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.nucmedbio.2014.02.008","article-title":"Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and melphalan chemotherapy","volume":"41","author":"Gouard","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0053","first-page":"76","article-title":"Single-dose anti-CD138 radioimmunotherapy: Bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model","volume":"2015","author":"Fichou","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130249","article-title":"Combining \u03b1-radioimmunotherapy and adoptive T cell therapy to potentiate tumor destruction","volume":"10","author":"M\u00e9nager","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0055","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.leu.2403948","article-title":"CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target","volume":"19","author":"Robillard","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0056","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0609.2006.00661.x","article-title":"Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma","volume":"77","author":"Sahara","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0057","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0058","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2001-12-0322","article-title":"Bismuth-213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts","volume":"100","author":"Sandmaier","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0059","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2002-12-3867","article-title":"Selective T-cell ablation with bismuth-213-labeled anti-TCR\u03b1\u03b2 as nonmyeloablative conditioning for allogeneic canine marrow transplantation","volume":"101","author":"Bethge","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.TP.0000128853.62545.B2","article-title":"Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation study","volume":"78","author":"Bethge","year":"2004","journal-title":"Transplantation"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0061","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/TP.0b013e3181d98c3d","article-title":"Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation","volume":"89","author":"Nakamae","year":"2010","journal-title":"Transplantation"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0062","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","article-title":"Durable donor engraftment after radioimmunotherapy using \u03b1-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0063","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2012-11-467035","article-title":"Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model","volume":"121","author":"Orozco","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0064","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1073\/pnas.97.4.1802","article-title":"Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity","volume":"97","author":"Axworthy","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2002-01-0107","article-title":"Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213","volume":"100","author":"Zhang","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0066","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1073\/pnas.0437788100","article-title":"Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia\/lymphoma xenografts","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0067","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2011-04-347039","article-title":"Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model","volume":"118","author":"Pagel","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0068","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1158\/1078-0432.CCR-11-1204","article-title":"Pretargeted radioimmunotherapy using genetically engineered anti-body-streptavidin fusion proteins for treatment of non-Hodgkin lymphoma","volume":"17","author":"Park","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.09.002_bib0069","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1874471011104030261","article-title":"Modelling and dosimetry for alpha-particle therapy","volume":"4","author":"Sgouros","year":"2011","journal-title":"Curr Radiopharm"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:34:54Z","timestamp":1757543694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299819300893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0001299819300893"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.09.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Alpha-Particle Therapy for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}